Investigational approaches to multiple sclerosis therapy

Area of Science:

• Neuroimmunology
• Therapeutic Development
• Multiple Sclerosis Research

Background:

• Multiple sclerosis (MS) research is shifting focus from relapse reduction to preventing disability progression and disease onset.
• New therapeutic goals in MS include halting disease advancement and promoting central nervous system (CNS) repair.

Purpose of the Study:

• To review emerging treatment strategies for multiple sclerosis (MS).
• To summarize advancements in next-generation immunomodulation, Epstein-Barr virus (EBV) targeted therapies, remyelination agents, and cell-based treatments for MS.

Main Methods:

• Review of current literature on emerging MS therapies.
• Analysis of clinical trial data for novel immunomodulatory agents, EBV-directed strategies, remyelination candidates, and cell-based therapies.

Main Results:

• Central nervous system (CNS) penetrant Bruton's tyrosine kinase (BTK) inhibitors show promise in slowing MS progression by targeting inflammation.
• Fc-silent CD40L blockade demonstrates efficacy in suppressing magnetic resonance imaging (MRI) activity in MS.
• Epstein-Barr virus (EBV)-directed strategies, including T-cell therapy and vaccines, are being explored to target a potential MS driver.
• Remyelination agents show biological activity but limited clinical benefit; cell-based therapies are in early phases with initial biological signals.

Conclusions:

• Advances in MS treatment signify a move towards precision immunomodulation and causal targeting.
• Bruton's tyrosine kinase (BTK) inhibitors and CD40L blockade are promising candidates for addressing MS progression.
• Future MS therapies will likely focus on CNS repair and targeting disease drivers like EBV.